⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCWB News
HCW Biologics Inc. Common Stock
Form 8-K
sec.gov
HCWB
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
globenewswire.com
HCWB
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
globenewswire.com
HCWB